Please login to the form below

Not currently logged in
Email:
Password:

WuXi PharmaTech potential USD 184.7m IPO

China-headquartered pharmaceutical and biotech company WuXi PharmaTech has released its initial public offering of 13,188,979 American Depositary Shares

China-headquartered pharmaceutical and biotech company WuXi PharmaTech (WuXi) has released its initial public offering (IPO) of 13,188,979 American Depositary Shares (ADSs).

Of the 13,188,979 ADSs sold in the offering, 10,000,000 ADSs were sold by WuXi, while 3,188,979 ADSs were sold by selling shareholders. The company has granted the underwriters a 30-day option to purchase up to an additional 1,978,347 ADSs to cover over-allotments.

WuXi says it should raise USD 107.8m from the sale, or USD 129.9m if underwriters exercise their options. The firm plans to use USD 40m to expand its Jingsu facility, USD 40m to build a new centre in Suzhou and the rest for general corporate purposes.

Each ADS represents eight ordinary shares and was priced at USD 14.00 per ADS. The ADSs will begin trading on the New York Stock Exchange on 9 August 2007 under the symbol 'WX.'

Credit Suisse Securities and J P Morgan Securities acted as representatives of the underwriters and joint book runners, while Jefferies & Company acted as co-manager for the offering.

WuXiís net revenue for Q1 FY07 rose 165 per cent on Q1 FY06 figures to rest at USD 33.8m. Net income was USD 6m, excluding pre-IPO stock compensation.

9th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....

Infographics